1-4 of 4
Jatin J. Shah
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma

Krina K. Patel, Jatin J. Shah, Lei Feng, Hans C. Lee, Elisabet M. Manasanch, Jasper Olsem, Ashley Morphey, Xiao Jiao Huo, Sheeba K. Thomas, Qaiser Bashir, Muzaffar H. Qazilbash, Donna M. Weber, Robert Z. Orlowski
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1277–1284.
https://doi.org/10.1158/1078-0432.CCR-21-3420
Published: 01 April 2022
View article titled, Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma
Open the PDF for Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma in another window
Includes: Supplementary data
Journal Articles

Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein–Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression

Richard J. Jones, Tawin Iempridee, Xiaobin Wang, Hans C. Lee, Janet E. Mertz, Shannon C. Kenney, Heather C. Lin, Veerabhadran Baladandayuthapani, Christopher W. Dawson, Jatin J. Shah, Donna M. Weber, Robert Z. Orlowski
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (19): 4901–4912.
https://doi.org/10.1158/1078-0432.CCR-15-2242
Published: 02 October 2016
View article titled, Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein–Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression
Open the PDF for Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein–Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression in another window
Includes: Supplementary data
Journal Articles

Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma

Jatin J. Shah, Andrzej J. Jakubowiak, Owen A. O'Connor, Robert Z. Orlowski, R. Donald Harvey, Mitchell R. Smith, Daniel Lebovic, Catherine Diefenbach, Kevin Kelly, Zhaowei Hua, Allison J. Berger, George Mulligan, Hélène M. Faessel, Stephen Tirrell, Bruce J. Dezube, Sagar Lonial
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (1): 34–43.
https://doi.org/10.1158/1078-0432.CCR-15-1237
Published: 03 January 2016
View article titled, Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma
Open the PDF for Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma in another window
Includes: Supplementary data
Journal Articles

Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia

Isere Kuiatse, Veerabhadran Baladandayuthapani, Heather Y. Lin, Sheeba K. Thomas, Chad C. Bjorklund, Donna M. Weber, Michael Wang, Jatin J. Shah, Xing-Ding Zhang, Richard J. Jones, Stephen M. Ansell, Guang Yang, Steven P. Treon, Robert Z. Orlowski
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (11): 2538–2545.
https://doi.org/10.1158/1078-0432.CCR-14-1462
Published: 31 May 2015
View article titled, Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia
Open the PDF for Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia in another window
Includes: Supplementary data